FDA Approves Tafasitamab-cxix for Relapsed or Refractory Follicular Lymphoma By Ogkologos - August 14, 2025 520 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR The (un)usual suspects – how early detection research embraces interdisciplinary science August 20, 2021 EMA Pharmacovigilance Risk Assessment Committee Advice on Safety-Related Aspects of the... February 19, 2021 Cabozantinib Plus Nivolumab and Ipilimumab Results in Longer PFS in Previously... May 19, 2023 Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has... May 15, 2019 Load more HOT NEWS PET-2-Guided BrECADD Better Tolerated and More Effective than eBEACOPP in Patients... A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... EMA Recommends Granting a Marketing Authorisation for Elinzanetant FDA Approves Pralsetinib for Lung Cancer with RET Gene Fusions
